BioStem Technologies, Inc. (OTCMKTS:BSEM - Free Report) - Investment analysts at Zacks Small Cap lifted their Q4 2024 earnings estimates for BioStem Technologies in a report issued on Friday, November 15th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings of $0.37 per share for the quarter, up from their previous estimate of $0.32. The consensus estimate for BioStem Technologies' current full-year earnings is $1.13 per share. Zacks Small Cap also issued estimates for BioStem Technologies' Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.61 EPS and FY2026 earnings at $2.39 EPS.
BioStem Technologies Stock Down 20.2 %
OTCMKTS:BSEM traded down 3.51 during mid-day trading on Monday, reaching 13.90. The company's stock had a trading volume of 259,200 shares, compared to its average volume of 34,615. The firm has a market capitalization of $231.02 million, a PE ratio of 20.44 and a beta of -0.36. The stock has a fifty day moving average of 13.52 and a 200-day moving average of 10.74. BioStem Technologies has a 1 year low of 2.34 and a 1 year high of 28.26.
BioStem Technologies (OTCMKTS:BSEM - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported 0.32 EPS for the quarter, topping analysts' consensus estimates of 0.31 by 0.01. The company had revenue of 82.56 million during the quarter, compared to the consensus estimate of 78.22 million.
About BioStem Technologies
(
Get Free Report)
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Recommended Stories
Before you consider BioStem Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.
While BioStem Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
